home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.53 +0.02 (+0.04%)

Official Closing Price Updated: 7:00 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

45 46 Next >

3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth ↗

February 21, 2024

Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop.

Via InvestorPlace

Dividend Income Update January 2024 ↗

February 15, 2024

It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio

Via Talk Markets

Looking Into GSK's Recent Short Interest ↗

February 12, 2024

Via Benzinga

Why Is Moderna Stock Trading Lower Today? ↗

February 09, 2024

Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer.

Via Benzinga

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

February 08, 2024

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally

From Alector, Inc.

Via GlobeNewswire

Recap: GSK Q4 Earnings ↗

January 31, 2024

Via Benzinga

Earnings Outlook For GSK ↗

January 30, 2024

Via Benzinga

23andMe Reports Third Quarter Fiscal 2024 Financial Results

February 07, 2024

Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473

From 23andMe, Inc.

Via GlobeNewswire

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

February 07, 2024

From Alector, Inc.

Via GlobeNewswire

Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?' ↗

February 06, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer believes in GSK plc (NYSE: GSK).

Via Benzinga

A Look Into GSK Inc's Price Over Earnings ↗

January 26, 2024

Via Benzinga

What the Options Market Tells Us About GSK ↗

January 09, 2024

Via Benzinga

GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

February 06, 2024

From GSK plc

Via Business Wire

The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024 ↗

February 06, 2024

Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements.

Via InvestorPlace

Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗

February 02, 2024

The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.

Via Benzinga

Topics Economy

Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option ↗

February 02, 2024

Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024.

Via Benzinga

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

What's Going On With GSK Stock Today? ↗

February 01, 2024

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

Via Benzinga

Topics Lawsuit

Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections ↗

January 31, 2024

Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired.

Via Investor's Business Daily

GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine ↗

January 31, 2024

GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.

Via Benzinga

Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗

January 31, 2024

The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.

Via Benzinga

Topics Economy

Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60% ↗

January 30, 2024

Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.

Via Benzinga

Earnings Scheduled For January 31, 2024 ↗

January 31, 2024

Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.

Via Benzinga

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology

January 24, 2024

From Elegen

Via Business Wire

GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M ↗

January 17, 2024

GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.

Via Benzinga

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles ↗

January 09, 2024

Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning

Via Benzinga

GSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio ↗

January 09, 2024

GSK plc (NYSE: GSK) has agreed to acquire Aiolos Bio Inc

Via Benzinga

GSK Enters Agreement to Acquire Aiolos Bio

January 09, 2024

From Aiolos Bio, Inc.

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com